

07 May 2026

## Endometrial Cancer

In the past three months, how many patients with endometrial cancer were treated with systemic anti-cancer therapy (SACT) at your trust? Please record the number of patients treated with each regimen, split by MMR status and line of therapy.

### Definitions

- **First line:** patient has received no prior SACT for endometrial cancer
- **Recurrent (2L+):** any treatment after first-line SACT, including second line and beyond
- **dMMR/MSI-H:** mismatch repair deficient or microsatellite instability-high
- **pMMR/MSS:** mismatch repair proficient or microsatellite stable
- If a patient's MMR status is untested or unknown, record them in the relevant 'Unknown MMR' column

Please enter 0 if no patients were treated with a given regimen. If a patient received more than one regimen in the period, record under the most recent.

07 May 2026

Treatment/Regimen	First Line			Recurrent (2L+)		
	dMMR/MSI-H	pMMR/MSS	Unknown MMR	dMMR/MSI-H	pMMR/MSS	Unknown MMR
<i>Immunotherapy combinations (checkpoint inhibitor + platinum-based chemotherapy)</i>						
Dostarlimab (Jemperli) + platinum-based chemotherapy	<5	0	0	<5	<5	0
Pembrolizumab (Keytruda) + platinum-based chemotherapy	0	<5	0	0	0	0
Durvalumab + platinum-based chemotherapy	0	0	0	0	0	0
<i>Immunotherapy monotherapy</i>						
Dostarlimab (Jemperli) monotherapy	0	0	0	<5	0	<5
Pembrolizumab (Keytruda) monotherapy	0	0	0	0	0	0
<i>Targeted combinations</i>						
Lenvatinib + Pembrolizumab (Lenvima + Keytruda)	0	0	0	0	0	0
<i>Chemotherapy</i>						
Platinum-based chemotherapy alone (monotherapy or combination with taxanes, anthracyclines or cyclophosphamide)	<5	19	10	0	<5	<5
<i>Other systemic treatments</i>						
Hormone therapy (Progesterone or Letrozole)	0	0	0	0	0	0
Any other SACT (please specify in comments)	0	0	0	0	<5	0
<b>Total</b>						

**07 May 2026**

Where numbers are low we have put <5 rather than state the actual figure. To ensure that patient(s) remain non identifiable. Disclosure of this information would breach the first data protection principle, which relates to the fair and lawful processing of personal data. Therefore, we have concluded that this information is exempt from disclosure under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party.